Good evening, everybody, or good morning, everybody. Thank you very much for joining Takeda's earnings conference call webinar for the first quarter FY 2022. I will serve as MC today. My name is Ayako Iwamuro, in charge of global IR. First, I will explain language setup. At the bottom of the Zoom screen, you'll find Language Selection. If you want to listen in Japanese, please select the Japanese audio. If you want English audio, then select English, or if you want original audio, please turn off this language function. For those who wish to listen to this call in English, please click the Language Selector button at the bottom of the Zoom window, and then select English. Before starting, I'd like to remind everyone that we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in our most recent Form 20-F and in other SEC filings of Takeda. Please also refer to the important notice on page two of the presentation. Let's move to the presentation today. We have with us Christophe Weber, President and CEO, R&D President, Andy Plump, and Chief Financial Officer, Costa Saroukos. They will be presenting. After the presentation, we will have a Q&A session. Please, let's start. Thank you, Ayako, and thank you everyone for joining us today. Our purpose is to create better health for people, brighter future for the world by discovering and delivering life-transforming treatments with a commitment to patients across the world, to our people, and to the planet. Needless to say that this purpose is more relevant than ever. It's not only a moral imperative to create shareholder and societal value, but it's also a way to make the company stronger. Our performance in the first quarter of this fiscal year reinforced our ability to drive long-term business growth. In the first quarter, core revenue was JPY 972.5 billion, with growth at a constant exchange rate of 8.3%, driven by our growth and launch products. Core operating profit for the quarter was JPY 319.1 billion, growing at an impressive 17% on a constant exchange rate basis. Core earnings per share grew 15.8% to JPY 145. This put us well on track towards our full year guidance for fiscal year 2022 of low single digit core revenue growth and high single digit core operating profit and core EPS growth at constant exchange rate. On a reported basis, our strong business performance, coupled with favorable foreign exchange, enabled us to deliver a reported revenue growth of 2.4%. This is despite the large gain of JPY 133 billion we booked as revenue in the first quarter of the last year related to the sale of a diabetes portfolio in Japan. On a reported profit basis, this one-time transaction had an impact on the first quarter growth rate, but our full year outlook still anticipate double digit reported operating profit and EPS growth. We continue to see progress in our commercial execution. Our diverse portfolio of growth on launched product grew at an impressive 26% at constant exchange rate, driven by ENTYVIO, TAKHZYRO, and our immunoglobulin franchise. At the same time, we are very much focused on our launch excellence, as I will detail in a few minutes. Andy will detail our pipeline progress shortly, so I would like to now give you an update on our most recent launches in the U.S.. Let's start with LIVTENCITY, which is redefining the way cytomegalovirus, or CMV, infection is treated. Patients now have access to a therapy that can enable sustained and effective treatment against post-transplant CMV infection, which could save an organ or a life that might otherwise be lost. As CMV is one of the most common and serious post-transplant infection, recent data support the meaningful impact we are seeing. At a recent medical meetings, we presented data on a new exploratory analysis showing that patients treated with LIVTENCITY had reduction in hospitalization and length of hospital stay compared to those treated with conventional antiviral therapies. We are also seeing promising momentum since the launch in December 2021. 56% of the 314 U.S. transplant centers have initiated therapy with at least one patient, and demand is continuing to grow. Our global expansion plan is underway with an EU approval decision expected in second half of fiscal year 2022. We also anticipate phase III data for LIVTENCITY, which could extend use in first line. We expect the readout at some point later this fiscal year. We are very proud of the impact of these transformative treatments. Patients who would otherwise be vulnerable to CMV now have hope and a better quality of life. I'd like to talk about another launch product, EXKIVITY. EXKIVITY is an important new treatment for adult patients with locally advanced or metastatic non-small cell lung cancer. This is the first and only approved oral therapy designed to target EGFR exon 20 insertion mutation for patients whose disease has progressed on or after platinum-based chemotherapy. The very unique and distinct value of this important treatment, combined with our launch capability, is driving its success. We see it in the continued progress following the launch in the U.S.. We are continuing to see better than expected new patient start and have now reached 50% exon 20 market share in U.S. Following approval in the U.S. and the U.K., we continue to receive approval from health authorities around the world, most recently in Switzerland, Australia, and South Korea. However, in the EU we decided to withdraw the EU marketing authorization application filing in second line non-small cell lung cancer following discussion with the CHMP, where the committee indicated that additional clinical data would be needed to confirm benefit for mobocertinib in the second line. Pending outcome from the phase III trial in first line EGFR exon 20 insertion non-small cell lung cancer, we plan to pursue approval in the EU This first line trial is event-driven and is targeted for submission in fiscal year 2024. We remain confident that EXKIVITY offers an effective treatment option for patients suffering from this difficult-to-treat cancer and are hopeful that we will continue to make important progress on bringing this treatment to patients in need. In closing, this quarter is yet another example of our ability to deliver on our mission to transform the life of patient while driving long-term financial growth. This result reinforce that our strategy is working, specifically the launch of our new innovative products, our deliberate investment in data and digital, and also commitment to sustainability. We have an incredibly exciting time ahead, patient by patient. We see the impact of our mission to transform life. I now would like to hand over to Andy to introduce our pipeline updates in more detail. Thank you. Thank you very much, Christophe, and hello to everyone on the call today. As Christophe mentioned, the impact we are seeing on the lives of patients is the key factor to our success. We see this impact so clearly as we make progress in our pipeline. The opportunity to bring transformative medicines to patients is an inspiring and motivating force for all of our scientists. I think you'll see this today as I walk through a few highlights from the first quarter. Next slide, please. There's a lot of enthusiasm here about our dengue vaccine. We recently presented the final data for TAK-003 and are very pleased with the long-term efficacy against hospitalizations as well as protection against dengue disease, which was maintained throughout the 4.5 years of our pivotal trial. We will share these results with you shortly. We reported positive phase III data for HYQVIA in CIDP, a chronic autoimmune and inflammatory disease that affects the peripheral nervous system. Most of the patients in the ADVANCE pivotal trial on active treatment received HYQVIA subcutaneously every four weeks. This convenient dosing and ability to self-administer at home has the potential to reduce the burden of chronic immunoglobulin treatment. Patients with alpha-1 antitrypsin-associated liver disease were treated with fazirsiran, our first-in-class RNAi therapy in an open-label phase II trial. The strong results were published in The New England Journal of Medicine, and highlights include the regression of fibrosis in 7 out of 12 patients and a median 83% reduction in accumulated Z-AAT protein in the liver. This is the key pathologic aggregate that causes inflammation and can lead to fibrosis and eventual liver transplant. These early results demonstrate the potential for fazirsiran to one day help these patients avoid liver transplant. Completing our clinical updates, TAK-280, a conditional B7H3 targeted bispecific T-cell engager designed to treat solid tumors, entered the clinic this quarter. This is the second program that we have entered into the clinic from Maverick Therapeutics, our build-to-buy acquisition completed last year. As Christophe highlighted earlier, we have in-licensed an exciting hyper-sialylated immunoglobulin candidate from Momenta Pharmaceuticals. This therapy has the potential to increase potency, allowing for significantly lower doses. If you go to the next slide 10, please. Here are our 10 late-stage development programs. Nuvaxovid was approved early this fiscal year and is now available in Japan, adding to the armament against COVID-19. Modakafusp alfa is our first-in-class immunocytokine that delivers an attenuated interferon to tumor and immune cells in a highly targeted manner. Updated results presented at the European Hematology Association for single-agent modakafusp alfa show an overall response rate of 43%, with multiple complete responses in heavily pretreated patients, importantly, including those refractory to anti-CD38 therapies. This quarter, we started the first of a series of phase II trials for modakafusp alfa, our lead innate immune program, which will define its path forward in relapsed or refractory multiple myeloma. Next slide, 11, please. We continue to be excited about our proof of concept readouts to come over the course of the next two years. These are the first of many new molecular entities that could emerge from our rich and transformative early-stage pipeline and add to our growing list of late-stage development programs. Next slide, 12, please. Here are select expansion opportunities we have for our major brands. We expect to file TAKHZYRO for the prevention of hereditary angioedema in children ages 2- 12 in the near future. This filing is based upon the outstanding data presented at the European Academy of Allergy and Clinical Immunology in July. TAKHZYRO demonstrated an approximately 95% reduction in HAE attacks when compared to baseline. Most of these children averaged nearly two attacks per month before entering the trial, and a majority of them remained attack-free during the full 52-week treatment period, a result not seen with any other agent. As mentioned, we also expect to file HYQVIA in the U.S. and EU as maintenance therapy for patients with CIDP based upon the positive results announced just this past month. Next slide 13. We have some key regulatory approvals and phase III readouts underway. Before we discuss our exciting data for TAK-003 and HYQVIA, we wanted to highlight upcoming data in Q2 for LIVTENCITY. As Christophe mentioned, we expect the top line phase III LIVTENCITY data in first line post-transplant CMV infection to read out in the second quarter. This trial compares LIVTENCITY against the current standard of care, valganciclovir, in patient with first CMV infections following a hematopoietic stem cell transplant. In phase II, LIVTENCITY showed a numerically higher rate of CMV viremia clearance versus valganciclovir, with a significantly lower rate of neutropenia at 5% versus 18%. Neutropenia is an independent predictor of mortality in stem cell transplant patients. LIVTENCITY's favorable safety profile, especially its lack of neutropenia, represents a potentially significant therapeutic advance for these patients. The late-stage data readout shown here will allow for global filing in these indications, with future label expansion opportunities to come. Now let's look at some of our data. If we can go to slide 14, please. As Christophe noted, we are very encouraged by the final 4.5 Year data from our dengue vaccine candidate, TAK-003. The analyses are complete, and the new drug application has been submitted in the EU. Dengue is a rapidly spreading mosquito-borne viral illness. It has been defined as a top 10 health problem by the World Health Organization. While mortality from dengue is relatively low, severe dengue infection can be devastating for patients, sometimes leading to hospitalization. For regions that experience a dengue epidemic, hospitals can become overrun with patients requiring supportive care. The secondary consequences for patients with other diseases can be substantial, not unlike what we have seen with COVID. There is an incredible unmet medical need, and we are ready to meet that need with a really good vaccine. Our 4.5-year data continue to support sustained efficacy. What we show here with patients at baseline who are seropositive or seronegative is an incredible 84% reduction in hospitalization. Hospitalization is an indicator of severe forms of dengue. As we have seen with COVID, it's not just if you can pre-prevent infection, but if you can prevent severe infection, it's clear that we can do both with our vaccine. Now, the efficacy does vary by serotype. We have strong efficacy in serotypes 1 and 2, which are the most common. We have strong efficacy in serotype 3 patients with previous dengue infections. However, we have no efficacy in serotype 3 patients who are seronegative, and to date, we do not have enough data in serotype 4 to draw conclusions. Now, allow me to highlight the hospitalization data from the last 18 months of the trial in the lower right. We are most reassured by the zero hospitalizations seen in the seronegative arm for patients on TAK-003 versus placebo. We believe these data will be reassuring to physicians and importantly regulators. We are currently under review in the EU. We believe these data continue to support a favorable benefit risk profile and are hopeful for a positive decision in the next few months. If we can go to the next slide 15, please. CIDP is a rare autoimmune and inflammatory disorder that causes demyelination and damage to peripheral nerves. The exact cause is unknown, but patients feel progressive weakness and impaired sensory function in their legs and arms, often leading to pain, fatigue, and other symptoms. This is a chronic condition that requires long-term therapy. The treatment goal is to maintain durable remission with therapies such as IVIG. IVIG, of course, can have its own challenges due to the need for venous access by a healthcare provider. A facilitated subcutaneous immunoglobulin like HYQVIA should help address an important need for patients with CIDP. We are very excited by the positive results in this phase III study. In the ADVANCE-1 trial, the HYQVIA arm showed a significant difference in relapse rate compared with the placebo arm when used as maintenance therapy in CIDP patients with a favorable safety profile. Importantly, most of the patients achieved these results with a once every four-week dosing regimen using HYQVIA, which is less frequent than any conventional subcutaneous immunoglobulin on the market. These data will be presented at an upcoming medical meeting and be used to file for approval in both the U.S. and EU later this fiscal year. We conclude with two exciting data sets that in the near future could bring new therapies and indications to benefit our patients. Thank you, and I will now turn it over to Costa. Costa. Thank you, Andy, and hello, everyone. This is Costa Saroukos speaking. It's my pleasure to explain the fiscal 2022 first quarter financial highlights. We are off to a strong start in fiscal 2022, with core revenue growing at 8.3% at constant exchange rate and 19.1% when factoring in the FX tailwind. This strong performance was driven by global and launch products such as ENTYVIO, TAKHZYRO, and immunoglobulin as we delivered growth in all geographic regions. In addition, we also are excited with what we've seen so far in the new launches of LIVTENCITY and EXKIVITY. Our reported revenue growth was 2.4%, impacted by the JPY 133 billion gain from the sale of the Japan diabetes business that was booked in Q1 of the prior year. This one-time event is the only difference between reported and core revenue. Our core operating profit, which excludes this divestiture gain, grew 17% at constant exchange rate to JPY 319.1 billion for the quarter. Our core operating profit margin was 32.8%, an increase of 2.3 percentage points on a year-over-year basis. This was partly because of the resolution of the ENTYVIO shipment phasing that we experienced in quarter four and partly a reflection of our broad-based portfolio growth and focus on cost control. Net debt to adjusted EBITDA remains at 2.8 x despite the year-end dividend payment. On all measures, we are on track towards the full year management guidance we provided in May. Let me go into more detail on the Q1 revenue performance versus prior year on slide 19. On the left-hand side, you can see a waterfall chart for reported revenue, which grew at 2.4% despite the full impact of the JPY 133 billion we booked in Q1 of last year from the sale of Japan diabetes portfolio. Core revenue on the right-hand side excludes this, and you can see our business momentum was driving 8.3% growth at constant exchange rate. Foreign exchange has also been a significant tailwind for us due to the depreciation of the yen, adding over 10 percentage points of growth to core revenue in the quarter. On slide 20, we show the drivers of reported and core operating profit for the quarter. Reported operating profit was JPY 150.5 billion, a decline of 39.4% versus prior year. Again, the decline is predominantly coming from the sale of the Japan diabetes portfolio last year. However, because that was a one-off event in quarter one of prior year, the impact will diminish over the remainder of this fiscal year. We are forecasting full-year reported operating profit growth of 12.8%. Core operating profit was JPY 319.1 billion, with our business momentum driving 17% growth at constant exchange rate and foreign exchange, an incremental tailwind of around 11 percentage points. On slide 21, you can see our growth by key business area. We have a balanced growing portfolio. Our growth and launch products continue to be key drivers, generating $2.7 billion of revenue in the quarter and delivering 26% growth at constant exchange rate. GI, our largest business area by revenue, grew at 15%, with growth of ENTYVIO across all markets, driven by continued share growth in bio naive patients. In rare disease, which grew 7%, we see continued demand growth and geographic expansion for TAKHZYRO, as well as a successful new launch of LIVTENCITY. PDT Immunology continues to be very strong, with 18% growth, which I will introduce in more detail on the next slide. You'll note that oncology business area is declining year-on-year, as was expected, given VELCADE generics entered the U.S. market from May this year. Neuroscience continues to be strong, driven by Vyvanse and Trintellix, and the other segment has benefited from revenue from our COVID-19 vaccines in Japan. I mentioned our strong and sustained performance in plasma-derived therapies, where we have successfully navigated pandemic pressures. Looking ahead, we have considerable potential to continue to grow this business and extend the impact of our therapies to new patient populations around the world. This quarter is evidence of that. Our PDT Immunology business delivered revenue growth of 18%, tracking towards the high end of our full year guidance. Within this, our Immunoglobulin portfolio grew at 22%, fueled by increased global demand, coupled with steady and growing supply. Our primary objective is to maintain continuity of patient supply, which requires consistent plasma volume growth as new patients are brought onto therapy. We have delivered plasma donation volumes above pre-pandemic levels for over one year and continue to build on this momentum. The growth of our BioLife network is a key factor. We added eight donation centers in the U.S. in the first quarter, bringing our global donation network to 212, and we are on track to increase year-on-year donation volumes by 10%-20% in fiscal year 2022. The past two years have demanded that we do more with less plasma, and we have. We are actively managing costs on a number of fronts to improve margins, including donor compensation. In quarter one, we reduced donor compensation by approximately 15% compared to a year ago, leveraging new data and analytics capabilities. We are also positioned to capture the full benefit of our digital and organization transformation to improve PDT business margins over time. Slide 23 shows the net balance compared to the end of March. Free cash flow was JPY 42.6 billion, reflecting a step up in CapEx that captures two oncology acquisitions, GammaDelta and Adaptate, which we completed in April this year. Also in April, we completed the share buyback initiated last year, and in June, we paid the second half-year dividend for fiscal year 2021. Despite the dividend payment, the completion of the buyback and step up in CapEx, we were able to hold net debt to adjusted EBITDA at 2.8 x. On slide 24, you can see our debt maturity ladder as of June. We paid down JPY 20 billion of USD-denominated debt in April and still expect to pay down a total JPY 500 billion of debt in fiscal year 2022. I'm very pleased with how we structured our debt profile, with a weighted average interest rate of approximately 2%, and importantly, 98% of our total debt at fixed interest rates. In fact, the only outstanding debt still at floating rates will mature this year. By the end of fiscal year 2022, we expect to be at 100% fixed rates. This gives us strong protection from any potential interest rate hikes. Furthermore, the currency breakdown of our debt very closely matches our cash flows, so we are also protected against major currency fluctuations. On slide 25, we show the guidance we disclosed on May 11. We are on track and make no changes at this point. Our forecast is based on an FX rate assumption of JPY 119 to the US dollar and JPY 133 to the euro. If we apply the June-end FX rates to the rest of fiscal year 2022, for example, JPY 136 to the US dollar, we would expect to see over 10 percentage points of incremental growth to our forecast for revenue, core operating profit, and core EPS. To be precise, core revenue will be growing at around 19% and our core operating profit and core EPS at 29% and 28% respectively. We continue to expect to generate JPY 600 billion-JPY 700 billion of free cash flow. Finally, we remain fully committed to our dividend of JPY 180 per share. To close out on the presentation on slide 26, I'd like to re-emphasize the key elements of our strategy to deliver sustainable growth and value for our shareholders. We continue to see strong momentum from our commercial portfolio, which enabled us to deliver 8.3% core revenue growth at constant exchange rate. While we do face some loss of exclusivity headwinds in the next two years, we expect momentum of our growth and launch products to support the top line over that period. Our margins are strong, with 32.8% core operating profit margin in Q1, and we delivered core operating profit growth of 17% at constant exchange rate, well on track towards our full year guidance of high single digit. Our success is built on our solid financial foundation, with robust cash flow that we will continue to allocate towards growth opportunities, continue deleveraging, and competitive shareholder returns. We have abundant liquidity and a well-structured debt profile of 98% fixed rate at an average cost of 2%, which positions us well in the changing macro environment. In closing, we believe that Takeda is in a position of strength. Our Q1 results demonstrates a strong start to fiscal year 2022, and we are well on track towards our guidance for the full year. We look forward to taking your questions, and thank you for your time. Thank you. Now we'd like to take questions. We have Christophe, Andy, Costa, and Masato Iwasaki, Japan General Affairs, with us in answering to your questions. If you have a question, please click Raise a Hand feature of Zoom. If you are participating in Japanese, please ask your questions in Japanese. If you are in English line, please ask your question in English. If you are listening to the live speech, turn off the interpretation feature, then you may be able to ask a question either in Japanese or English. There are so many participants today and so many people raising a hand. Please limit the number of your question up to two per person. Please lay out all the question, the two questions that you have at the beginning. Thank you for your cooperation and understanding. First, Mr. Yamaguchi over Citigroup, you are raising your hand. Please go ahead. Can you hear me okay? Thank you very much. This is Yamaguchi from Citi. Two questions, please. The first question is regarding Q1 situations. You hinted that the full year number will surpass the full year guidance if you use a current currency. Can you tell me, even if you use the CER basis, I think your performance Q1 so far looks better than the full year number. Can you give me the comment whether even using a CER, your Q1 may be better than the full year number, and why? That's the first question. The second question is that, regarding 003 dengue vaccine, Andy-san hinted that there might be some decision within a few months, which is a really good comment. Can you give me the why you think it's a few months? You did have interaction with the EU authorities, then you are now coming up to the conclusion, just awaiting the decision from the EU, should happen within a few months. Thank you for the two questions. Costa, can you answer to the first question regarding the full year guidance, whether you may be exceeding already in the first quarter? Yes. Thank you very much, Yamaguchi-san, for your question. Firstly, let me say that we are very happy with the start of the year. Our financials, our growth, even at a constant exchange rate, our margins, really you know, we're doing well. It's good start to the year. Having said that, of course, we're continuing to monitor the situation. In particular, the VELCADE generic penetration and erosion in the U.S. is something that we continue to look at. We had generic entry in May, so you know, already in May of this year. So we're monitoring that situation. We have seven generics that have already entered into the market in the U.S. We also expect another 10 generics coming in the coming weeks. Obviously, this is something that we have factored into our forecast for the full year, but we'll continue to monitor and hopefully, you know, quarter two will be another strong quarter, and we can perhaps come back to you and update you accordingly there for the full-year guidance. Thank you very much. Yamaguchi-san, this is Andy. Thank you very much for your question on 003, and I think you essentially answered your own question. Just to remind everybody, we submitted the original dossier to the special track in the EU called EU-Medicines for all. It's a process whereby countries outside of the EU can actually leverage the opinion if they choose. They can leverage the opinion from the EU, so it allows the medicine to be made available well beyond the EMA countries. We filed initially based on our three-year dataset, and as we're engaging in discussions with the EMA, we made the decision to pause the file and include our 4.5-year dataset. As you saw from the data we presented today, and as has been out in the public domain, the 4.5-year data look quite remarkable and continued to support the overall benefit risk profile of the vaccine. We've now submitted those data, and we're going through a process of discussions, ongoing discussions with the EU, and we expect to have a CHMP opinion and hopefully a positive decision later this year. Thank you. Thank you very much, Mr. Yamaguchi. Next question from Nomura Securities, Mr. Koutani. Please unmute yourself. Hello, this is Koutani, Nomura Securities. Can you hear me? Yes, we can hear you. Go ahead. Thanks for taking my questions. I have two questions, if I may. One is about ENTYVIO. When we look at the competitive landscape for IBD, it seems like there will be a lot of new entrants in the next two years. There's RINVOQ. I think there's SKYRIZI, which received approval for Crohn's disease in June. Within the next two years, there will be SKYRIZI in ulcerative colitis. I think mirikizumab from Lilly launching in ulcerative colitis, etrasimod from Pfizer. I understand that none of these drugs have really demonstrated a clear advantage over ENTYVIO in terms of clinical remission or endoscopic remission or things that actually matter in IBD. I also understand that none of these new entrants are going to report head-to-head results versus HUMIRA, like what ENTYVIO did with VARSITY trial. We're relatively confident that ENTYVIO will maintain growth. Is Takeda worried about ENTYVIO growth possibly slowing down in the 2023-2024 timeframe when Vyvanse is going off patent? That's the first question. The second question is about the pipeline, specifically modakafusp alfa and subasumstat, because curiously, both of these drugs involve interferon and very interesting. For modakafusp alfa, there's a trial for combination therapy with KEYTRUDA in solid tumors, specifically melanoma. It says the trial ends in August 2023. Since interferon is likely to strengthen PD-1 activity, if we see any ORR in primary PD-1-resistant melanoma, wouldn't that be considered POC? Why isn't this listed on page 10 or 11? For subasumstat, I assume we'll be seeing results in MSS CRC first and then NSCLC and cervical cancer later. I couldn't find much scientific evidence to corroborate the involvement of interferon specifically in MSS CRC. How confident is Takeda in showing activity in this very difficult subset? Those are the two questions for me. Thank you. Thank you very much for the question. It's Christophe here. I think you know well the IBD market and ENTYVIO has established a very strong track record of efficacy and safety since its launch more than seven years ago. We have established also a superiority against TNF-alpha. The TNF-alpha class still has a very significant market share in this market, so there is still a lot to do. Today we are the leading therapy of choice for bio-naive patients. We are very much aware of the competition. It's a very dynamic market. We believe that ENTYVIO is extremely well-positioned. We have not seen a product which has any demonstration of superiority. Yes, there will be more competition, but this is also a disease where there is a lot of churn among treatment. Still a lot to do to continue to establish the best standard of care, which is ENTYVIO today, when you think that the TNF-alpha class still has a very significant market share in this market. Very confident about ENTYVIO. We also plan to launch a subcutaneous formulation in the U.S. in the coming years that will add more dynamic also to the product. Very confident about the continuous growth of ENTYVIO in the future. Koutani-san, thank you very much for the questions about modakafusp alfa and subasumstat. As you mentioned, these are both agents that work at least in part through an interferon alpha-based mechanism and are representative really of our oncology strategy to focus on innate immune mechanisms. Firstly, for modakafusp alfa, our focus right now is really on melanoma, where we've seen very compelling evidence of clinical activity in highly refractory patients. Our focus for modakafusp is in building out that profile in refractory patients and also moving up in lines of therapy through combination therapies. We'll be starting over the course of the next few months combination trials, initially with daratumumab and then with other agents. The studies that you're mentioning in solid tumors are still quite exploratory. We're still in the process of understanding dose, safety profile. We've been hesitant to define a date for when we might have PSC, because we're still working through, you know, a number of issues. With respect to subasumstat, which is also a really exciting mechanism that works at least in part through interferon alpha signaling, and we've published quite extensively on the translational data that we've seen in humans in terms of immune activation with this mechanism. Our challenge has been understanding, you know, where exactly to target into what tumor, and so we're looking across a range of different tumor types. The three that are most actively enrolling right now are combination studies on top of PD-1 inhibitors. The first is in microsatellite-stable colorectal cancer. We're also looking in non-small cell lung cancer and of course, in melanoma. The first dataset that we'll have read out will be in the microsatellite-stable colorectal population. It's incredibly challenging population to see benefits in. We'll wait and see what that dataset looks like. We actually had some partial responses in our phase I, phase II study, which is the. You asked about rationale. That was the rationale for proceeding in that difficult population. I think our focus, given the biology, will be more on the melanoma and non-small cell lung cancer populations. Thank you very much. Thank you, Koutani-san. Next is Kyogi-san, Cowen. Please unmute and please speak. Hello, everyone. Thank you so much for taking our question. Just a couple on our end. Maybe starting with the positive HYQVIA results in CIDP. Could you discuss the total opportunity and growth prospects in the immunoglobulin for immunoglobulins in this space, especially in light of CSL's subcu Hizentra? Just in general, how do you see the market being segmented and evolve over time? The second one is on the Arrowhead collaboration. We noticed that the phase II placebo-controlled study results are expected sometime in the fall, according to clinicaltrials.gov. Do you expect to present these results at an academic conference? Can you just walk us through the next steps towards regulatory filing and the opportunity here? Thank you so much. Thank you very much, Kyogi. It's Christophe here. Look, the immunoglobulins are well known to treat CIDP, so this is not a new as such a treatment. What is new in the case of HYQVIA is that it's one of the most convenient subcutaneous formulation. We believe that will really help patients with their treatment. We don't have the indication of CIDP in the U.S. We don't have it for our IV as well as for our subcu. We believe that nevertheless, our product are used, but we never had the indication. I think it's really great for us first to be able to have this to file this indication for HYQVIA. Again, HYQVIA is a very competitive device and a very competitive formulation, very convenient for patients. We think that the efficacy combined with this convenience will be a big add and a big plus for the patients. The CIDP indication overall, let me remind you that overall, the CIDP indication represent about 20% of the overall immunoglobulin market globally. This is Andy, Kyogi-san. On the Arrowhead TAK-999 question. Just again to remind you, just the data that we've seen so far in the open label study, ongoing open label study has been just so remarkable in terms of the percent knockdown. We're seeing 90% knockdown of the mutant alpha-1 antitrypsin RNA. We're seeing almost 85% knockdown of the mutant protein aggregate. We're seeing trends towards reductions in liver function tests. On biopsy, again, non-controlled setting, but we're seeing actually a regression in fibrosis over very short time periods of 24 and 48 weeks. The data that we've seen to date are compelling enough to drive a go decision for a pivotal study. The placebo-controlled blinded phase II data that will be coming out later this year, of course, those data will be presented at congress. It's important to note that that study is being run by our collaborator, Arrowhead, so they'll be responsible for that presentation. I think that data set will be important in helping us further understand the overall profile of the molecule. We believe based on the data that we've seen so far that we have enough compelling evidence to move forward. We strongly believe. That we're going to need a full phase III study for approval. Our hope is that we'll be starting that phase III study, you know, this year. The specific endpoints for that study, we're in the process of discussing those with FDA and other agencies. Thank you so much. Very helpful. Congratulations on your progress. Thank you very much. Next question from JP Morgan Securities, Mr. Wakao. Please unmute yourself. Wakao from JP Morgan. My first question is about PDT business and the cost structure. Compared to the fourth quarter, this first quarter, cost has improved, and you showed the donor fee lowered. When do you expect the results of lower donor fee impacting positively on cost? This donor fee is that incorporated into your guidance for the year? The second question is regarding SG&A. The first quarter SG&A, in spite of cheaper yen, it is well controlled. That's my impression. I'm aware you are not specifically disclosing SG&A, but can you comment on the current situation against your plan? There could be some negative impact from yen depreciation going forward, but do you think the first quarter trend in SG&A will continue to the second quarter? Thank you. Thank you very much, Wakao-san, for your question. Now, on the first one, on the PDT reduction and we firstly don't disclose margins, but what I can say is that the reduction in the donor fees has been factored into our full year guidance. So that's one thing. On the SG&A controls, you're right. We have, you know, we're seeing a reduction in overall SG&A, predominantly driven by the investments that we've done in the past and currently on data, digital, and technology. In respect to sales and marketing, we're leveraging data digital technology, in particular around omni-channel targeting with physicians, et cetera. On the G&A side, we're seeing some significant savings coming through, again, leveraging data digital technology automation and leveraging our Takeda Business Solutions centers, where we are increasing a number of back office transactional activity, in particular around HR, procurement and finance, and that's helping overall improve productivity and efficiency. We're very pleased with the progress there and we'll continue to manage this moving forward. Thank you for your question. Thank you very much, Wakao-san. Next question. Daiwa Securities, Hashiguchi-san, please. This is Hashiguchi. Thank you very much. I have one question. Regarding the COVID-19 vaccine sales, I understand that the full year forecast is JPY 50 billion. What is the revenue in the first quarter? The latest forecast, do you think that it's likely that you'll be exceeding JPY 50 billion? Thank you very much, Hashiguchi-san. It's Costa here. Revenue for the first quarter was JPY 19.4 billion, which is a combination of both Spikevax and Nuvaxovid. At this stage, we're holding on the target of the JPY 50 billion, so no further update at this stage. We're very happy with the start of the fiscal year. That's where we're tracking, JPY 19.4 billion for Q1, and we're maintaining the guidance of JPY 50 billion for the full year. Thank you. Thank you very much. Mr. Hashiguchi, thank you very much. Next question from Credit Suisse Securities, Mr. Sakai. Please unmute yourself and ask your question. Hello, this is Sakai speaking from Credit Suisse. Two questions. The trend of LIVTENCITY and EXKIVITY, the first quarter seems to be little bit lower than, or actually our expectations. When we're gonna see the spike in the sales trend, going forward. Now, you mentioned about important first line indications for both drugs, but that's three year away. What's gonna be the trigger for, you know, the spike in the share. I mean, the sales trend for these two important, supposedly important, new products? That's the first question. Second question is TAK-861. If I'm not mistaken, you are going to have the internal readout of the phase I data sometime in August. Once you find any new. Well, if it's a good result or bad result, what is your plan to disclose the, you know, the outcome of this early readout? That's my two questions. Thank you. Thank you, Sakai-san. It's Christophe here. I think we are not disappointed at all by the Q1 actually. We are very pleased with the uptake, but you know, when you launch a product like LIVTENCITY, first you need to have the product reference in the different transplant center. I think we have achieved that very, very well. The majority of the transplant center now have referenced LIVTENCITY. 56% of the 314 transplant center in the U.S. have already used it. It will take a while to translate that into revenue, but it will happen. Then of course, the first line is key here. The majority of the value will be in the first-line indication, so we'll see it starting next year and the year after. That's LIVTENCITY. Keep in mind also that LIVTENCITY overall potential, revenue potential is higher than EXKIVITY as well. And on EXKIVITY, it's also the first line is also very critical. The first-line indication is also very critical. This is where there is the highest market value. I think this product will be successful. You know, the early signs are very strong that these two products will be very successful. We just need to have the full set of indications to translate that into revenue potential. Sakai-san, on TAK-861, just to be clear, and I'm sorry if there was a misunderstanding. We will not have a data set that will enable us to make a decision, a go/no-go decision in August. What we've disclosed is that we'll have a decision, a go/no-go decision by the end of this year. So just so that we're clear in terms of timelines. End of this year, that's what you're saying right now? That's right. That's I think what we've been guiding all along. You know, nothing's changed since we made the transition from 994 to 861 in terms of our acceleration. You know, the data set that will enable this trend, this decision will be healthy volunteers sleep deprived data, and then also type 1 narcolepsy patients treated for a month. We're in the process of, you know, accumulating that blinded data set now. Okay. Thank you. Sakai-san, thank you. Next is Goldman Sachs, Ueda-san, please. Hi, can you hear me? Hi. I have one question. The question for the narcolepsy franchise. The company decided the discontinuation of the development TAK-994 based on the clinical data. Could you share your thoughts on the factors behind the, you know, development suspension for the TAK-994? And whether, you know, you think those factors will affect the safety profile of TAK-861. Thank you. Thank you very much. We discontinued TAK-994 because of a drug-induced liver injury signal that we don't believe is class related or mechanism based, but molecule related. TAK-861 is a unique molecule with a very different profile to TAK-994. It's a much more potent molecule, and it has a very different exposure profile. Part of what we're doing in the context of our phase one studies is we're trying to understand what the overall profile of TAK-861 and whether it's gonna have, you know, an efficacy and safety profile that's gonna be distinct from TAK-994. That will be what will drive the go/no-go decision into phase II. Thank you so much. Thank you very much. It's time to close. With this, we'd like to close today's webinar. Thank you very much for your participation. When you have further questions, please contact IR members regarding the financial situation. Thank you very much for your participation today. With this, we close today's conference call. Thank you. Thanks, everyone. Bye for now.